• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Successful treatment with venetoclax and demethylation drugs in one acute myeloid leukemia patient relapsed after cord blood stem cell transplantation: a case report and literature review].[1例脐带血干细胞移植后复发的急性髓系白血病患者使用维奈托克和去甲基化药物成功治疗：病例报告及文献复习]
Zhonghua Xue Ye Xue Za Zhi. 2019 Dec 14;40(12):1050-1051. doi: 10.3760/cma.j.issn.0253-2727.2019.12.017.
2
Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.维奈托克联合地西他滨可诱导造血干细胞移植后复发的急性髓系白血病完全缓解并伴有分子学反应。
Am J Hematol. 2019 Feb;94(2):E48-E50. doi: 10.1002/ajh.25352. Epub 2018 Nov 29.
3
Ambulatory Hematopoietic Stem Cell Transplantation in Young Adults with Acute Myeloid Leukemia Treated with Venetoclax and Low Doses of Cytarabine: Report of Two Cases.年轻成人急性髓细胞白血病患者采用维奈托克联合小剂量阿糖胞苷行门诊造血干细胞移植：两例报告。
J Adolesc Young Adult Oncol. 2019 Aug;8(4):481-483. doi: 10.1089/jayao.2018.0137. Epub 2019 Mar 4.
4
Venetoclax-induced panniculitis in an acute myeloid leukemia patient.维奈托克诱发急性髓系白血病患者发生脂膜炎。
Ann Hematol. 2021 May;100(5):1333-1334. doi: 10.1007/s00277-020-04372-0. Epub 2021 Jan 13.
5
Venetoclax and decitabine for relapsed paediatric myelodysplastic syndrome-related acute myeloid leukaemia with complex aberrant karyotype after second stem cell transplantation.维奈托克与地西他滨用于二次干细胞移植后复发的伴有复杂异常核型的小儿骨髓增生异常综合征相关急性髓系白血病
Br J Haematol. 2020 Jun;189(6):e251-e254. doi: 10.1111/bjh.16682. Epub 2020 Apr 28.
6
Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy.基于低强度维奈托克的挽救性治疗作为急性髓系白血病患者在传统强化化疗失败后进行异基因干细胞移植的桥梁。
Leuk Res. 2024 Jan;136:107429. doi: 10.1016/j.leukres.2023.107429. Epub 2023 Nov 23.
7
Successful venetoclax and Actinomycin D-based treatment for relapsed acute myeloid leukemia post allogeneic hematopoietic cell transplantation.基于维奈托克和放线菌素D成功治疗异基因造血细胞移植后复发的急性髓系白血病。
Bone Marrow Transplant. 2021 Nov;56(11):2626-2627. doi: 10.1038/s41409-021-01434-3. Epub 2021 Aug 10.
8
Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.维奈托克联合阿扎胞苷治疗难治性急性髓系白血病和混合表型急性白血病后行单倍体相合移植的疗效
Br J Haematol. 2020 Jun;189(5):e200-e204. doi: 10.1111/bjh.16622. Epub 2020 Apr 3.
9
Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML.基于维奈托克的疗法作为复发/难治性急性髓系白血病儿童异基因造血细胞移植的桥梁。
Bone Marrow Transplant. 2023 Mar;58(3):328-331. doi: 10.1038/s41409-022-01877-2. Epub 2022 Nov 29.
10
Venetoclax for Refractory Myeloid Sarcoma.维奈托克用于治疗难治性髓系肉瘤
J Oncol Pract. 2019 Jul;15(7):413-415. doi: 10.1200/JOP.18.00753.

本文引用的文献

1
Autoimmune hemolytic anemia, adverse event to venetoclax.自身免疫性溶血性贫血，维奈托克的不良事件。
Farm Hosp. 2019 Sep 1;43(5):166-167. doi: 10.7399/fh.11230.
2
Allosteric modulation of sigma receptors by BH3 mimetics ABT-737, ABT-263 (Navitoclax) and ABT-199 (Venetoclax).BH3 模拟物 ABT-737、ABT-263（Navitoclax）和 ABT-199（Venetoclax）对 sigma 受体的别构调节。
Pharmacol Res. 2019 Apr;142:87-100. doi: 10.1016/j.phrs.2019.01.040. Epub 2019 Feb 3.
3
Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells.基因生物标志物可预测急性髓系白血病细胞对双靶向BCL-2和MCL-1治疗的反应。
Oncotarget. 2018 Dec 28;9(102):37777-37789. doi: 10.18632/oncotarget.26540.
4
The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL.CAR T 细胞疗法之旅：儿童和青年复发性或难治性 B-ALL 的体验。
Blood Cancer J. 2019 Jan 22;9(2):10. doi: 10.1038/s41408-018-0164-6.
5
The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.Bcl-2 抑制剂 venetoclax 抑制 AML 中低甲基化药物诱导的 Nrf2 抗氧化通路激活。
J Cell Physiol. 2019 Aug;234(8):14040-14049. doi: 10.1002/jcp.28091. Epub 2019 Jan 8.
6
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.维奈托克联合地西他滨或阿扎胞苷治疗初治老年急性髓系白血病患者。
Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
7
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
8
The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.用于治疗慢性淋巴细胞白血病的BCL-2抑制剂的研发与当前应用
Curr Hematol Malig Rep. 2017 Feb;12(1):11-19. doi: 10.1007/s11899-017-0359-0.
9
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.维奈托克联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病：一项1b期研究
Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.
10
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.维奈托克单药治疗急性髓性白血病患者的II期研究中的疗效及反应的生物学关联
Cancer Discov. 2016 Oct;6(10):1106-1117. doi: 10.1158/2159-8290.CD-16-0313. Epub 2016 Aug 12.

[Successful treatment with venetoclax and demethylation drugs in one acute myeloid leukemia patient relapsed after cord blood stem cell transplantation: a case report and literature review].

作者信息

Tong J, Yao W, Liu H L, Zheng C C, Geng L Q, Zuo X Y, Tang B L, Wan X, Zhou L, Song K D, Zhang X H, Sun Z M

机构信息

Department of Hematology, First Affiliated Hospital of China University of Science and Technology (Anhui Provincial Hospital), Hefei 230001, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2019 Dec 14;40(12):1050-1051. doi: 10.3760/cma.j.issn.0253-2727.2019.12.017.

DOI:10.3760/cma.j.issn.0253-2727.2019.12.017
PMID:32023741
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7342675/
Abstract
摘要